Description
Carvejohn (Carvedilol) 6.25 mg
Carvejohn 6.25 mg is a branded tablet presentation of carvedilol, a cardiovascular medicine used to manage certain conditions involving high blood pressure and heart failure. It belongs to the beta-blocker class and also has additional vasodilating activity, which means it can lower heart rate and reduce vascular resistance. The exact approved uses can vary by country and product licence, but carvedilol is an established treatment in cardiovascular care.
Active Ingredient and Medicine Class
The verified active ingredient is carvedilol. It is a non-selective beta-adrenergic blocker with alpha-1 blocking activity. This combination gives carvedilol both heart-rate-lowering and blood-vessel-relaxing effects. It is widely recognised as a cardiovascular medicine used in the management of hypertension and heart failure.
Established Medical Uses
Official prescribing information identifies carvedilol for hypertension, chronic heart failure, and left ventricular dysfunction after myocardial infarction in clinically stable patients. In heart failure, it is used as part of long-term cardiovascular therapy rather than as a rapid symptom-relief medicine. Its role is to help improve haemodynamic control and, in appropriate patients, support long-term clinical outcomes.
How It Works
Carvedilol blocks beta receptors in the heart and blood vessels, which reduces sympathetic stimulation, slows the heart rate, and decreases the force of contraction. Its alpha-1 blocking effect helps relax blood vessels, lowering peripheral resistance and blood pressure. In heart failure, these combined effects can reduce the workload on the heart and may help improve cardiac function over time.
Important Safety Information
Carvedilol is not suitable for everyone. Important contraindications include bronchial asthma or related bronchospastic conditions, second- or third-degree atrioventricular block, sick sinus syndrome, severe bradycardia unless a pacemaker is present, cardiogenic shock, decompensated heart failure requiring intravenous inotropic therapy, severe hepatic impairment, and previous serious hypersensitivity to carvedilol or related products. Clinically important precautions include the risk of bradycardia, hypotension, worsening heart failure or fluid retention, bronchospasm in susceptible patients, and masking of hypoglycaemia symptoms in people with diabetes. Relevant interactions include medicines that slow heart rate or conduction, certain calcium-channel blockers, digoxin, amiodarone, clonidine-like agents, insulin or oral hypoglycaemics, and drugs that affect carvedilol metabolism.
Possible Side Effects
Reported adverse effects include dizziness, fatigue, hypotension, bradycardia, diarrhoea, asthenia, weight increase, and changes in blood glucose. Less common but potentially serious reactions may include marked slowing of the pulse, fainting, worsening heart failure, bronchospasm, severe allergic reactions, and liver-related problems. As with other beta-blockers, abrupt discontinuation can be risky in some patients.
Scientific Evidence
Human clinical evidence supports carvedilol as an effective beta-blocker with vasodilating properties in cardiovascular disease. Randomised and comparative studies in chronic heart failure have shown improvement in ventricular function and clinical outcomes, and the medicine has been associated with reductions in mortality and hospitalisation in selected patient groups. Review literature also describes benefit in hypertension and in left ventricular dysfunction after myocardial infarction. Overall, the research supports carvedilol as a well-established option in guideline-based cardiovascular therapy, while recognising that tolerability and suitability depend on the individual clinical context.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, local prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / U.S. prescribing information CARVEDILOL tablets, for oral use. View official prescribing information
- Philip A Poole-Wilson et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. The Lancet, 2003. View scientific article
- Tarek Ajam et al. Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction. American Heart Journal, 2018. View scientific article